Literature DB >> 32483387

Chromosomal translocation-derived aberrant Rab22a drives metastasis of osteosarcoma.

Dan Liao1, Li Zhong1, Junqiang Yin2, Cuiling Zeng1, Xin Wang1, Xingchuan Huang3, Jinna Chen4, Hong Zhang1, Ruhua Zhang1, Xin-Yuan Guan1,4, Xintao Shuai5, Jianhua Sui3, Song Gao1, Wuguo Deng1, Yi-Xin Zeng1, Jing-Nan Shen6, Jian Chen7, Tiebang Kang8.   

Abstract

Osteosarcoma is a type of aggressive malignant bone tumour that frequently metastasizes to lungs, resulting in poor prognosis. However, the molecular mechanisms of lung metastasis of osteosarcoma remain poorly understood. Here we identify exon-intron fusion genes in osteosarcoma cell lines and tissues. These fusion genes are derived from chromosomal translocations that juxtapose the coding region for amino acids 1-38 of Rab22a (Rab22a1-38) with multiple inverted introns and untranslated regions of chromosome 20. The resulting translation products, designated Rab22a-NeoFs, acquire the ability to drive lung metastasis of osteosarcoma. The Rab22a1-38 moiety governs the function of Rab22a-NeoFs by binding to SmgGDS-607, a GTP-GDP exchange factor of RhoA. This association facilitates the release of GTP-bound RhoA from SmgGDS-607, which induces increased activity of RhoA and promotes metastasis. Disrupting the interaction between Rab22a-NeoF1 and SmgGDS-607 with a synthetic peptide prevents lung metastasis in an orthotopic model of osteosarcoma. Our findings may provide a promising strategy for a subset of osteosarcoma patients with lung metastases.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32483387     DOI: 10.1038/s41556-020-0522-z

Source DB:  PubMed          Journal:  Nat Cell Biol        ISSN: 1465-7392            Impact factor:   28.213


  47 in total

1.  WHO Classification of Soft Tissue and Bone, fourth edition: summary and commentary.

Authors:  Andrew E Rosenberg
Journal:  Curr Opin Oncol       Date:  2013-09       Impact factor: 3.645

2.  [WHO classification of tumours of soft tissue and bone 2013: the main changes compared to the 3rd edition].

Authors:  Iva Zambo; Karel Veselý
Journal:  Cesk Patol       Date:  2014-04

Review 3.  Translational biology of osteosarcoma.

Authors:  Maya Kansara; Michele W Teng; Mark J Smyth; David M Thomas
Journal:  Nat Rev Cancer       Date:  2014-10-16       Impact factor: 60.716

4.  Bone cancer incidence by morphological subtype: a global assessment.

Authors:  Patricia C Valery; Mathieu Laversanne; Freddie Bray
Journal:  Cancer Causes Control       Date:  2015-06-09       Impact factor: 2.506

5.  Bone cancers.

Authors:  H D Dorfman; B Czerniak
Journal:  Cancer       Date:  1995-01-01       Impact factor: 6.860

6.  Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program.

Authors:  Lisa Mirabello; Rebecca J Troisi; Sharon A Savage
Journal:  Cancer       Date:  2009-04-01       Impact factor: 6.860

7.  Massive genomic rearrangement acquired in a single catastrophic event during cancer development.

Authors:  Philip J Stephens; Chris D Greenman; Beiyuan Fu; Fengtang Yang; Graham R Bignell; Laura J Mudie; Erin D Pleasance; King Wai Lau; David Beare; Lucy A Stebbings; Stuart McLaren; Meng-Lay Lin; David J McBride; Ignacio Varela; Serena Nik-Zainal; Catherine Leroy; Mingming Jia; Andrew Menzies; Adam P Butler; Jon W Teague; Michael A Quail; John Burton; Harold Swerdlow; Nigel P Carter; Laura A Morsberger; Christine Iacobuzio-Donahue; George A Follows; Anthony R Green; Adrienne M Flanagan; Michael R Stratton; P Andrew Futreal; Peter J Campbell
Journal:  Cell       Date:  2011-01-07       Impact factor: 41.582

8.  Recurrent somatic structural variations contribute to tumorigenesis in pediatric osteosarcoma.

Authors:  Xiang Chen; Armita Bahrami; Alberto Pappo; John Easton; James Dalton; Erin Hedlund; David Ellison; Sheila Shurtleff; Gang Wu; Lei Wei; Matthew Parker; Michael Rusch; Panduka Nagahawatte; Jianrong Wu; Shenghua Mao; Kristy Boggs; Heather Mulder; Donald Yergeau; Charles Lu; Li Ding; Michael Edmonson; Chunxu Qu; Jianmin Wang; Yongjin Li; Fariba Navid; Najat C Daw; Elaine R Mardis; Richard K Wilson; James R Downing; Jinghui Zhang; Michael A Dyer
Journal:  Cell Rep       Date:  2014-04-03       Impact factor: 9.423

9.  Exome sequencing of osteosarcoma reveals mutation signatures reminiscent of BRCA deficiency.

Authors:  Michal Kovac; Claudia Blattmann; Sebastian Ribi; Jan Smida; Nikola S Mueller; Florian Engert; Francesc Castro-Giner; Joachim Weischenfeldt; Monika Kovacova; Andreas Krieg; Dimosthenis Andreou; Per-Ulf Tunn; Hans Roland Dürr; Hans Rechl; Klaus-Dieter Schaser; Ingo Melcher; Stefan Burdach; Andreas Kulozik; Katja Specht; Karl Heinimann; Simone Fulda; Stefan Bielack; Gernot Jundt; Ian Tomlinson; Jan O Korbel; Michaela Nathrath; Daniel Baumhoer
Journal:  Nat Commun       Date:  2015-12-03       Impact factor: 17.694

10.  Unscrambling the genomic chaos of osteosarcoma reveals extensive transcript fusion, recurrent rearrangements and frequent novel TP53 aberrations.

Authors:  Susanne Lorenz; Tale Barøy; Jinchang Sun; Torfinn Nome; Daniel Vodák; Jan-Christian Bryne; Anne-Mari Håkelien; Lynnette Fernandez-Cuesta; Birte Möhlendick; Harald Rieder; Karoly Szuhai; Olga Zaikova; Terje C Ahlquist; Gard O S Thomassen; Rolf I Skotheim; Ragnhild A Lothe; Patrick S Tarpey; Peter Campbell; Adrienne Flanagan; Ola Myklebost; Leonardo A Meza-Zepeda
Journal:  Oncotarget       Date:  2016-02-02
View more
  9 in total

1.  Acetylation dependent functions of Rab22a-NeoF1 Fusion Protein in Osteosarcoma.

Authors:  Xiaoting Liang; Xin Wang; Yaohui He; Yuanzhong Wu; Li Zhong; Wen Liu; Dan Liao; Tiebang Kang
Journal:  Theranostics       Date:  2020-06-19       Impact factor: 11.556

2.  Selective Targeting of Class I Histone Deacetylases in a Model of Human Osteosarcoma.

Authors:  Haydee M Torres; Ashley M VanCleave; Mykayla Vollmer; Dakota L Callahan; Austyn Smithback; Josephine M Conn; Tania Rodezno-Antunes; Zili Gao; Yuxia Cao; Yohannes Afeworki; Jianning Tao
Journal:  Cancers (Basel)       Date:  2021-08-20       Impact factor: 6.639

3.  The Construction and Development of a Clinical Prediction Model to Assess Lymph Node Metastases in Osteosarcoma.

Authors:  Wenle Li; Shengtao Dong; Bing Wang; Haosheng Wang; Chan Xu; Kai Zhang; Wanying Li; Zhaohui Hu; Xiaoping Li; Qiang Liu; Rilige Wu; Chengliang Yin
Journal:  Front Public Health       Date:  2022-01-06

4.  Circ_0007385 regulates cell proliferation, apoptosis and stemness via targeting miR-493-3p/RAB22A axis in non-small cell lung cancer.

Authors:  Dongxiao Ding; Feng Yang; Zhongjie Chen; Junjie Ying
Journal:  Thorac Cancer       Date:  2022-01-05       Impact factor: 3.500

5.  Long Noncoding RNA LINC00909 Induces Epithelial-Mesenchymal Transition and Contributes to Osteosarcoma Tumorigenesis and Metastasis.

Authors:  Wanshun Liu; Qi Zhang; Kai Shen; Keran Li; Jie Chang; He Li; Ao Duan; Sheng Zhang; Yumin Huang
Journal:  J Oncol       Date:  2022-10-10       Impact factor: 4.501

6.  LRIG2 regulates cell proliferation, migration and apoptosis of osteosarcoma.

Authors:  Zhi-Qiang Li; Wei-Jie Liao; Bo-Lin Sun; Zhi-Wen Luo; Nan-Shan Zhong; Jia-Bao Wu; Zhi-Li Liu; Jia-Ming Liu
Journal:  BMC Cancer       Date:  2022-10-01       Impact factor: 4.638

Review 7.  SmgGDS: An Emerging Master Regulator of Prenylation and Trafficking by Small GTPases in the Ras and Rho Families.

Authors:  Anthony C Brandt; Olivia J Koehn; Carol L Williams
Journal:  Front Mol Biosci       Date:  2021-06-16

8.  Rab22a-NeoF1: a promising target for osteosarcoma patients with lung metastasis.

Authors:  Kai Xie; Xinyi Zhang; Yongguang Tao
Journal:  Signal Transduct Target Ther       Date:  2020-08-24

9.  Rab22a-NeoF1 fusion protein promotes osteosarcoma lung metastasis through its secretion into exosomes.

Authors:  Li Zhong; Dan Liao; Jingjing Li; Wenqiang Liu; Jingxuan Wang; Cuiling Zeng; Xin Wang; Zhiliang Cao; Ruhua Zhang; Miao Li; Kuntai Jiang; Yi-Xin Zeng; Jianhua Sui; Tiebang Kang
Journal:  Signal Transduct Target Ther       Date:  2021-02-11
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.